Ysios Capital, a European venture capital firm specialized in life sciences and a Catalonia.health member company, has announced the launch of InceptionBio, a new fund with a target size of €100 million focused on biotech company creation and early-stage project development.
First Closing with CDTI Participation
The fund has already completed a first closing, with participation from the Centro para el Desarrollo Tecnológico y la Innovación (CDTI) through its SICC Innvierte program, which supports investment in high-potential innovative companies.
InceptionBio will focus on identifying, developing and building new companies around high-quality science, with a particular focus on Spain. The fund will primarily invest in technology transfer opportunities and early-stage companies, enabling Ysios to work closely with universities, research centers and scientific entrepreneurs to accelerate the translation of scientific discoveries into new therapies that can deliver meaningful impact for patients.
Leadership and Strategy
The initiative will be led by Joan Perelló, Managing Partner, and Arturo Urrios, Partner, who bring extensive experience in biomedical innovation, venture capital and company creation. This new strategy complements Ysios Capital's existing investment approach and expands its ability to engage from the earliest stages.
Joan Perelló stated: "Spain has world-class science and a unique opportunity to translate that science into globally impactful biotech companies. With InceptionBio, we aim to further strengthen our ability to engage at the earliest stages of innovation, working closely with the scientific ecosystem to build companies that can deliver meaningful solutions for patients."
InceptionBio's strategy combines building new companies around scientific assets emerging from universities and research centers with identifying and attracting international assets that can be developed in Spain. Through this strategy, Ysios aims to strengthen the Spanish biotech ecosystem and help position Spain as a leading biotech hub.
2026 Objectives
The fund already has a pipeline of investment opportunities in advanced review and aims to support the creation of at least three new biotech companies in 2026.
Arturo Urrios, Partner at Ysios Capital, added: "We see a significant opportunity to identify differentiated scientific assets, translate them into high-potential companies, and attract the talent and capital needed to develop them. InceptionBio was created to connect science, entrepreneurship and investment, working closely with both the public and private sectors to accelerate company creation across Europe, with a clear focus on Spain."
Comments